Ideal Microbiological and Pharmacological Characteristics of a Quality Antimicrobial Agent: Comparing Original and Generic Molecules

References

• Cohen M.L. Changing patterns of infectious disease. Nature 2000; 406 (6797): 762–767.
   PubMed Web of Science ®Google Scholar
• Janssens JP, Krause KH. Pneumonia in very old. Lancet Infectious Diseases 4: 112–24, 2004.
   PubMed Web of Science ®Google Scholar
• Mandell GL, Bennett JE, Dolin R (Eds). Mandell, Douglas and Bennett's - Principles and Practice of Infectious Diseases. 5th Edition, Elsevier/Churchill Livingstone, New York, NY 2005.
   Google Scholar
• Pittet D. Nosocomial bloodstream infections. In: Wenzel RP (Ed), “Prevention and Control of Nosocomial Infections” 2nd ed. Baltimore, Williams & Wilkins 1993: 512-555.
   Google Scholar
• Novelli A, Adombri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet. 2005; 44 (5): 539–49.
   PubMed Web of Science ®Google Scholar
• Roberts SJ, Bateman DN, Smith JM. Prescribing behav-iour in general practice: the impact of promoting therapeuti-cally equivalent cheaper medicines. Br J Gen Pract. 1997 Jan; 47 (414): 13–8.
   PubMed Web of Science ®Google Scholar
• Magazzini L, Pammolli F, Riccaboni M. Dynamic compe-tition in pharmaceuticals. Patent expiry, generic penetration, and industry structure. Eur J Health Econ. 2004 Jun; 5 (2): 175–82.
   PubMedGoogle Scholar
• Committee for Proprietary Medicinal Products (CPMP) of the European Agency for Evaluation of Medicinal Products (EMEA). Note for guidance for the investigation of bioavailabil-ity and bioequivalence. EMEA, London - 26 July, 2001. www.eudra-org/emea.html (last accessed January 2, 2006).
   Google Scholar
• Fry DE. The importance of antibiotic pharmacokinetics in criticall illness. Am J Surg 1996; 172(Suppl 6A): 205-255.
   Google Scholar
• De Paepe P, Belpaire FM, Buylaert WA. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002; 41 (14): 1135–1151.
   PubMed Web of Science ®Google Scholar
• Pinder M, Bellomo R, Lipman J. Pharmacological prin-ciples of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002; 30 (2): 134–144.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacody-namics of sepsis - Review. Clin Pharmacokinet. 2006; 45 (8): 755–773.
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for thera-peutic failure in patients with septic shock. Crit Care Med 2001; 29 (2): 385–391.
   PubMed Web of Science ®Google Scholar
• Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic vari-ability - Review. Clin Pharmacokinet. 2005; 44 (10): 1009–1034.
   PubMed Web of Science ®Google Scholar
• Bulfoni A, Concia E, Costantino S, et al. Orientamenti terapeutici per il trattamento delle sepsi e delle endocarditi in medicina interna.Giornale Ital Med Interna 2004; 3 (1/2), Suppl.2: 1-102.
   Google Scholar
• Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damian' D, Casini M, Furlanut M. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004; 43 (6): 405–15.
   PubMed Web of Science ®Google Scholar
• Ogunbona FA, Akanni AO. Comparative bioavailability studies on some brands of ampicillin capsules. Pharmazie 1985; 40 (7): 479.
   PubMed Web of Science ®Google Scholar
• Lohitnavy 0, Lohitnavy M, Sareekan K, Polnok S, Taytiwat P. Average bioequivalence of generic clarithromycin tablets in healthy Thai male volunteers. Biopharm Drug Dispos 2003; 24 (6): 229–231.
   Google Scholar
• Ilupeju TO, Oladeinde FO, Olaniyi AA, Amosu MA. Bioequivalence study of three generic formulations of co-tri-moxazole tablets in human urine. Afr J Med Med Sci 2004; 33 (4): 341–345.
   PubMedGoogle Scholar
• Semde R, Ouedraogo HW, Guissou IP, Amighi K. Bioequivalence in vitro evaluation of some antibacterial gener-ic dosage forms. J Pharm Belg 2005; 60 (2): 51–55.
   PubMedGoogle Scholar
• Pineyro-Lopez A, Pineyro-Garza E, Torres-Alanis O, et al. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult vol-unteers. Clin Ther 2006; 28 (1): 110-115.
   PubMed Web of Science ®Google Scholar
• Leelarasamee A, Tatong W, Kasattut N, Sriboonruang T, Ayudhya DP. Bioequivalence study of clindamycin phos-phate injection (Clinott-P) in Thai healthy volunteers. J Med Assoc Thai 2006; 89 (5): 683–689.
   PubMedGoogle Scholar
• Nightingale CH A survey of the quality of generic clar-ithromycin products manufactured in Slovenia and Israel. Adv Ther 2000; 17 (3): 167–178
   Google Scholar
• Henwood SQ, De Villiers MM, Liebenger W, et al. Solubility and dissolution properties of generic rifampicin raw materials. Drug Develop and industrial Pharmacy 2000; 26 (4): 403–408.
   PubMed Web of Science ®Google Scholar
• Cuadrado A, Gascon AR, Solinis MA et al. Bioequivalence of two oral ciprofloxacin tablets formulations. Int J Clin Pharmacol Ther 2004; 42 (6): 336–341.
   PubMed Web of Science ®Google Scholar
• weir RE, Zaidi FH, Charter's DG, Bunce C, Soltani M, Lovering AM. Variability in the content of Indian generic ciprofloxacin eye drops. Br J Ophthalmol 2005; 89 (9): 1094-1096.
   Google Scholar
• Conte JE Jr. Comparative antibacterial activity of Vancocin and generic vancomycin. Antimicrob Agents Chemother 1987; 31 (2): 333–334.
   PubMed Web of Science ®Google Scholar
• Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother 1998; 42 (5): 1303–1304.
   PubMed Web of Science ®Google Scholar
• Finch RC, Eliopoulos GM. Safety and efficacy of gly-copeptide antibiotics. J Antimicrob Chemother 2005; 55 Suppl 2: ii 5-13.
   Google Scholar
• Marchese A, Debbia EA, Bacca D, Balistreri G, Musolino B, Schito GC. Multidrug-resistant gram-positive pathogens. An update on current microbiological patterns. Drugs 1997; 54 Suppl 6: 11–20.
   Google Scholar
• Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 2006; 368 (9538): 874–885.
   PubMed Web of Science ®Google Scholar
• Pace JL, Yang G. Glycopeptides: Update on an old successful antibiotic class. Biochem Pharmacol 2006; 71 (7): 968–980.
   PubMed Web of Science ®Google Scholar
• Rice LB. Antimicrobial resistance in gram-positive bac-teria. Am J Med 2006; 119(6 Suppl 1): S11-S19.
   Google Scholar
• Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis 2006; 42 Suppl 1: S25–S34.
   PubMedGoogle Scholar
• Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin Pediatr Infect Dis 2006; 17 (3): 113–119
   PubMedGoogle Scholar
• Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality asso-ciated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteraemia: a meta-analysis. Clin Infect Dis 2003; 36 (1): 53–59.
   PubMed Web of Science ®Google Scholar
• Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319 (3): 157–161.
   PubMed Web of Science ®Google Scholar
• Uttley AH, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988; 1(8575-6): 57–58.
   PubMed Web of Science ®Google Scholar
• Frieden TR, Munsiff SS, Low DE et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet. 1993; 342 (8863): 76–79.
   PubMed Web of Science ®Google Scholar
• Marchese A, Balistreri G, Tonoli E, Debbia EA, Schito GC. Heterogeneous vancomycin resistance in methicillin-resis-tant Staphylococcus aureus strains isolated in a large Italian hospital. J Clin Microbiol 2000; 38 (2): 866–869.
   PubMed Web of Science ®Google Scholar
• Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 Suppl 1: S13–S24.
   PubMedGoogle Scholar
• Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance asso-ciated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006; 50 (9): 3039–3047.
   PubMed Web of Science ®Google Scholar
• Appelbaum PC. The emergence of vancomycin-inter-mediate and vancomycin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2006; 12 Suppl 1: 16–23.
   PubMedGoogle Scholar
• Parenti F, Schito GC, Courvalin P. Teicoplanin Chemistry and Microbiology. J Chemother 2000; 12 Suppl 5: 5–14.
   PubMedGoogle Scholar
• Sakoulas G, Moellering RC Jr, Eliopoulos GM. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy. Clin Infect Dis 2006; 42 Suppl 1: S40–S50.
   PubMedGoogle Scholar
• Martinez JL, Baquero F. Mutation frequencies and antibiotic resistance. Antimicrob Agents Chemother 2000; 44 (7): 1771–1777.
   PubMed Web of Science ®Google Scholar
• Muoghalu BU, Lattimer GL. Delayed red neck syn-drome with generic vancomycin. Drug Intell Clin Pharm 1988; 22 (2): 173.
   PubMedGoogle Scholar
• Bednarek M, Majda-Stanislawska E. Incidence of methi-cillin-resistant Staphylococcus aureus strains (MRSA) and diffi-culties in treatment. Own experience Przegl Epidemiol 2006; 60 (1): 49–52.
   PubMedGoogle Scholar
• Lambert PA, Conway BR. Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin. J Chemother 2003;15 (4): 357–368.
   PubMed Web of Science ®Google Scholar
• Schito GC, Keenan MH Predicting the clinical efficacy of generic formulations of ceftriaxone. J Chemother 2005;17 Suppl 2: 33–40.
   PubMedGoogle Scholar
• Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425–428.
   PubMed Web of Science ®Google Scholar
• Sádaba B, Azanza JR, Campanero MA, Garcia-Quetglas E. Relationship between pharmacokinetics and phar-macodynamics of I3-lactams and outcome. Clin Microbiol Infect 2004; 10: 990–998.
   PubMed Web of Science ®Google Scholar
• Odenholt I, Gustafsson I, Lowdin E, Cars O. Suboptimal antibiotic dosage as a risk factor for selection of penicillin-resistant Streptococcus pneumoniae: in vitro kinetic model. Antimicrob Agents Chemother 2003; 47 (2): 518–523.
   PubMed Web of Science ®Google Scholar
• Levy SB, Marshall B. Antibacterial resistance world-wide: causes, challenges and responses. Nat Med 2004;10(12 Suppl): S122–S129.
   PubMed Web of Science ®Google Scholar
• Agudelo M, Zuluaga AF, Rodriguez C, Salazar BE, Vesga O. Determination of therapeutic equivalence (TE) for 5 generic products (GP) of penicillin G (PEN) using the neu-tropenic murine thigh infection model (NMTIM). [Abstract A-1877]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p 40.
   Google Scholar
• Rodriguez C, Zuluaga AF, Salazar BE, Agudelo M, Vesga O. Experimental comparison of 11 generic products (GP) of oxacillin (OXA) with the original compound (OC) in terms of concentration of active principle (CAP), in vitro activ-ity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM). [Abstract A-1305]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p 28.
   Google Scholar
• Salazar BE, Zuluaga AF, Rodriguez C, Agudelo M, Vesga O. Experimental comparison of 7 generic products (GP) of lincomycin (LIN) with the original compound (OC) in terms of concentration of active priciple (CAP), in vitro activity, and in vivo efficacy, using the neutropenic murine thigh infection model (NMTIM). [Abstract A-1879]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p 41
   Google Scholar
• Zuluaga AF, Salazar BE, Loaiza SA, Agudelo M, Vesga O. Therapeutic equivalence (TE) with the original compound (OC) of 8 generic products (GP) of ampicillin (AMP) deter-mined in the neutropenic murine thigh infection model (NMTIM). [Abstract E-2033]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p 180. Zuluaga AF, Salazar BE, Galvis W, Agudelo M, Vesga O. In vivo bactericidal efficacy of 10 generic products (GP) of amikacin (AMK) compared with the original compound (OC) in the neutropenic murine thigh model (NMTIM). [Abstract A-1878]. In Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, Oct 30-Nov 2, 2004: p 41.
   Google Scholar